Factors Associated With Semaglutide Initiation Among Adults With Obesity.

ABSTRACT:

Importance

Semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, was approved for weight management in individuals with obesity in June 2021. There is limited evidence on factors associated with uptake among individuals in this subgroup without diabetes.

Objective

To explore factors associated with semaglutide initiation among a population of commercially insured individuals with obesity but no diagnosed diabetes.

Design, setting, and participants

This retrospective observational cohort study used data from the Merative MarketScan Commercial Claims and Encounters Database and included adults in the US aged 18 years or older with a first diagnosis of obesity in an outpatient or inpatient setting between June 5, 2021, and July 1, 2022. Inclus

SUBMITTER: Podolsky MI 

PROVIDER: S-EPMC11751746 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature